Comparative Pharmacology
Head-to-head clinical analysis: BALZIVA 21 versus NORTREL 1 35 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BALZIVA 21 versus NORTREL 1 35 21.
BALZIVA-21 vs NORTREL 1/35-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BALZIVA-21 is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) signaling by binding to VEGF-A and preventing its interaction with VEGF receptors (VEGFR-1 and VEGFR-2), thereby reducing angiogenesis and tumor vascularization.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, altering cervical mucus to impede sperm penetration, and inducing endometrial changes that reduce implantation likelihood.
BALZIVA-21 is administered 150 mg orally twice daily.
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
None Documented
None Documented
Terminal half-life: 18 hours (range 12-24 hr); prolonged in renal impairment
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-24 hours. Steady-state achieved after 10 days.
Renal: 70% unchanged; biliary/fecal: 20%; 10% metabolized
Renal 50-60% as metabolites, fecal 40-50% as conjugates, <1% unchanged
Category C
Category C
Oral Contraceptive
Oral Contraceptive